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A large amount of data supports a role for oxidized 
low density lipoprotein (oxLDL) in atherosclerotic lesion 
formation, while inappropriate platelet aggregation is an 
important factor in advanced lesion formation. For this 
reason, we investigated the effects of dietary vitamin E 
supplementation, an antioxidant, on platelet aggregation 
and oxidation of LDL in hypercholesterolemic rats, a 
generally accepted model of atherogenesis. Rats received 
normal chow (N) or chow containing 5% cholesterol (C) or 
chow containing 5% cholesterol plus vitamin E. All rats 
were maintained on the appropriate diet for a minimum of 
eight weeks. In both the C and E groups, plasma levels of 
total cholesterol and LDL cholesterol were significantly 
greater than in the N group (p<0.0001). Triglyceride 
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levels in the E group were significantly greater than in 
the N group (p<0.05), while HDL cholesterol levels were 
not significantly different between the three groups. 
Platelet aggregation was not significantly different 
between the hypercholesterolemic groups in response to 
either 0.5 mM arachidonic acid or 5 µM adenosine 
diphosphate. In both groups of rats whose diets were 
supplemented with cholesterol, the LDL ultra-
centrifugation fraction of plasma contained TEARS 
(thiobarbituric acid-reactive substances), which are 
indicative of oxidation. Vitamin E supplementation to the 
cholesterol diet significantly reduced TEARS in the LDL 
samples by 38% (p<0.02). These results provide evidence 
that vitamin E supplementation could be beneficial in 
reducing atherosclerotic disease. 
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INTRODUCTION 
Cardiovascular disease is the leading cause of death 
in the United States. In 1992, the latest year for which 
data are available, the death rate for all causes was 
2,177,000. Of this number, ischemic heart disease 
accounted for 480,200 deaths, cerebrovascular disease for 
143,600 deaths, and atherosclerosis for 16,100 deaths 
(U.S. Bureau of the Census, 1994). Thus, 29% of all 
reported deaths were a direct result of atherosclerotic 
processes. 
Evidence indicates that oxidation of low density 
lipoprotein (LDL) is a significant event in the 
atherosclerotic process. The main purpose of this study 
was to explore the effects of a dietary antioxidant on 
the oxidation of LDL and on the biological consequences 
produced by oxidized LDL. 
1 
Hypotheses of Atherosclerosis 
The Response-to-Injury Hypothesis 
In 1976, Ross and Glomset proposed the first widely 
accepted theory of the events which lead to athero-
sclerotic disease. The Response-to-Injury Hypothesis came 
out of the work from their laboratory as well as the 
earlier works of many others. They proposed that 
endothelial injury, especially focal desquamation, was 
the initiating event in atherosclerosis. This injury 
could occur via such factors as hyperlipidemia, hormone 
dysfunction, or mechanical stress due to hypertension. 
. . ' This desquamation would expose subendothelial connective 
tissue to platelets and other blood components. Platelets 
would then adhere to collagen, aggregate, and release the 
contents of their granules. This infiltration of platelet 
factors, along with lipoproteins and possibly other 
substances, would lead to focal smooth muscle cell (SMC) 
proliferation; the formation of increased extracellular 
matrix (ECM) components, ie. connective tissue; and the 
deposition of lipid in the ECM and in SMC. If the source 
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of this injury was removed, the lesion would regress. 
However, if the causative factors were constantly 
present, such as would be found in hypercholesterolemia, 
these events would continue unabated. This would 
eventually lead to atherosclerotic lesions. 
In this hypothesis, it was felt that the sub-
endothelium needed to be exposed for lesion initiation, 
and that SMC were the predominant cell type in early 
lesions. During the next decade, however, work by several 
investigators shed much new light on the process of 
lesion formation and the contents of the lesions 
themselves. 
Fatty streaks, which were found to occur early in 
life at anatomical sites where fibrous plaques typically 
develop, were shown to consist of lipid-laden macrophages 
with underlying lipid-laden SMC (Stary, 1983). 
Furthermore, several animal models of hyper-
cholesterolemia demonstrated that one of the earliest 
cellular interactions to occur was the attachment of 
monocytes to the endothelium (Faggiotto et al., 1984b; 
Joris et al., 1983; Silkworth et al., 1975; Gerrity, 
1981a). It was shown, both in monkeys (Faggiotto et al., 
3 
1984b) and rats (Joris et al., 1983), that monocytes 
gathered in clusters on the endothelium, migrated 
subendothelially, accumulated lipid, took on the 
appearance of foam cells, and finally led to the 
development of the fatty streak. Although monocytes had 
been shown to adhere preferentially to injured 
endothelium in culture (DiCorleto et al., 1985), both 
studies showed that these events occurred in the presence 
of an intact endothelium. The laboratory of Joris also 
found that platelet involvement was minimal at this 
stage. In both animal models, as lesion development 
progressed there was migration of monocytes, which 
differentiated into macrophages; lipid-filled SMC 
appeared, leading to streak enlargement and raised 
plaques; platelet involvement increased; and advanced SMC 
proliferative lesions appeared which contained a fibrous 
cap of SMC and connective tissue, with underlying cells, 
necrotic foam cells, extracellular lipids, collagen, and 
calcification. This picture of fibrous plaque composition 
was also demonstrated in humans (Ross et al., 1984). In 
the study of Faggiotto and Ross (1984), the increased 
platelet adherence and aggregation occurred only after 
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endothelial cells separated and retracted over fatty 
streaks at branch points. This led to mural thrombus 
formation. Also supporting the role of monocytes was the 
discovery that Interleukin-! (IL-1), produced by both 
macrophages and endothelial cells (EC), induced increased 
adherence of monocytes to the endothelium (Bevilacqua et 
al., 1985) . 
Much new evidence also emerged about the 
endothelium. It was shown to produce vasoactive agents 
(Moncada et al., 1977), growth factors (DiCorleto and 
Bowen-Pope, 1983), and growth inhibitors (Castellot et 
al., 1982). Individual EC were found to detach with rapid 
replacement, leading to non-denuding injury (Reidy and 
Schwartz, 1983; Reidy and Schwartz, 1984); and it was 
discovered EC bound low density lipoprotein (LDL) with a 
specific, high-affinity receptor, and modified and 
transcytosed it (Steinberg, 1983). 
Brown and Goldstein showed that cells have specific 
LDL receptors, and that LDL self-regulation occurs by 
controlling the number of receptors expressed, promoting 
the intracellular storage of cholesterol, and limiting 
the activity of HMG-CoA Reductase, the rate-limiting 
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enzyme in cholesterol biosynthesis (1984). It was also 
shown that LDL incubated in the presence of macrophages 
became oxidized, and that this LDL was cytotoxic to 
fibroblasts (Cathcart et al., 1985). Finally, Jackson and 
Gotto proposed that LDL may alter the cholesterol to 
phospholipid ratio of EC membranes, leading to increased 
membrane viscosity, decreased endothelial malleability, 
and possible EC retraction (Jackson and Gotto, 1976). 
New information concerning platelets also was 
discovered. Platelets contain platelet-derived growth 
factor (PDGF), which was shown to be mitogenic for SMC 
and a chemoattractant for both SMC and monocytes (Deuel 
et al., 1982; Grotendorst et al., 1982; Ross et al., 
1974). It was also shown to bind with high-affinity to 
SMC but not to EC (Bowen-Pope and Ross, 1982). Platelets 
also contain platelet factor 4 (PF4), which is released 
during the release action and was shown to be chemotactic 
for monocytes (Deuel et al., 1981). Finally, it was 
demonstrated that the extent of endothelial injury 
correlates linearly with the amount of platelet 
accumulation (Reidy et al., 1983); and that intimal 
proliferative lesions will not form in cases of 
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endothelial denudation when platelets are absent 
(Friedman et al., 1977; Moore et al., 1976). 
From this and other evidence, Ross (1986) made 
several general conclusions. He felt that monocyte 
involvement precedes SMC accumulation in fatty streak 
formation; that monocytes are the predominant cell type 
in fatty streaks, while SMC are predominant in fibrous 
plaques; that macrophages secrete growth factors for SMC 
and EC; that macrophages can injure EC by forming toxic 
substances and by oxidizing LDL; that EC normally inhibit 
platelet release by producing vasoactive agents and by 
their nonthrombogenic surface, and that platelet 
adherence to modified EC may not be a common event; that 
platelet interaction with the subendothelium leads to the 
release of their granule contents; and that SMC can 
respond to a variety of chemotactic factors. This led him 
to conclude that "it is probably not necessary in many 
cases for endothelial disjunction, retraction, or 
subendothelial exposure to occur for atherosclerosis to 
develop", and to propose the Revised Response-to-Injury 
Hypothesis. 
7 
The Revised Response-to-Injury Hypothesis 
This hypothesis, like the earlier one, is based on 
endothelial injury. However, Ross recognized that 
"injury" need not mean denudation, but could include 
events which precipitate biological changes in EC. He 
proposed both a short path and a long path to fibrous 
plaque formation. In the long path, injury may lead to 
growth factor secretion by EC. Monocytes then attach to 
the endothelium and also secrete growth factors. These 
monocytes migrate to the subendothelium, continue to 
release growth factors such as PDGF, and lead to fatty-
streak formation. Fibrous plaque formation then occurs 
via one of two paths: 1) the release of growth factors 
from macrophages and EC may lead to direct conversion, or 
2) macrophages may stimulate or injure the overlying 
endothelium, leading to EC loss, platelet attachment, 
additional growth factor release, and eventual conversion 
to fibrous plaques. In the short path, EC may be injured 
yet remain intact, leading to increased EC turnover; 
increased formation of growth factors by EC; and intimal 
SMC migration with concomitant PDGF production. This 
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would presumably lead to fibrous plaque formation. 
While this hypothesis recognized the newly 
discovered role of monocytes, it still did not place much 
emphasis on the role of LDL in lesion development. It had 
been known for several years that lesion cholesterol 
originated primarily from plasma lipoproteins; and 
epidemiological studies had linked increased levels of 
plasma LDL and cholesterol with accelerated atherogenesis 
and increased mortality from coronary heart disease 
(Keys, 1970; Steinberg, 1983). It had also been 
demonstrated that most foam cells arise from plasma 
monocytes (Aqel et al., 1984; Bylock and Gerrity, 1988; 
Faggiotto et al., 1984). But how did these cells 
accumulate enough lipid to become foam cells? As 
mentioned earlier, Brown and Goldstein had shown that the 
uptake of LDL led to the down-regulation of the number of 
LDL receptors expressed, and thus to a decrease in LDL 
uptake. It had also been discovered that foam cells occur 
in rabbits and humans deficient in LDL receptors (Buja et 
al., 1983; Rosenfeld et al., 1987); and that neither 
monocytes nor macrophages could be converted to foam 
cells when incubated with high concentrations of LDL 
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(Goldstein et al., 1979). Thus, a receptor-independent 
pathway of LDL uptake seemed to be involved. 
Part of the answer lay in the discovery of a 
receptor on macrophages which mediated the uptake and 
degradation of LDL which had been chemically modified by 
acetylation (Goldstein et al., 1979). This receptor took 
up concentrations of acetyl-LDL which were 20 times the 
amount taken up of native LDL (nLDL), yet this receptor 
did not bind nLDL. The result of this uptake was the 
formation of foam cells. This receptor was dubbed the 
"scavenger" receptor, and was subsequently found on EC. 
However, acetyl-LDL had never been demonstrated in vivo, 
so foam cell formation remained in part a mystery. 
This mystery was solved with the discovery that 
incubation of nLDL with SMC or EC led to a three- to ten-
fold increase in it's uptake by macrophages, and that 
this uptake was primarily via the scavenger receptor 
(Heinecke et al., 1984; Henriksen et al., 1983; Morel et 
al., 1984). It was later shown that monocytes and 
macrophages themselves could induce similar changes to 
nLDL (Cathcart et al., 1985; Parthasarathy, 1986a). These 
changes, producing a product commonly referred to as 
10 
oxidized-LDL (oxLDL), are numerous. The initial step is 
always the peroxidation of polyunsaturated fatty acids 
(PUFA) found in the lipid portion of LDL. This has been 
shown to be totally inhibited by the presence of 
antioxidants (Morel et al., 1984; Steinbrecher et al., 
1984) or plasma. These modifications have also been shown 
to be absolutely dependent on the presence of small 
amounts of iron or copper, and perhaps on a cellular 
lipoxygenase activity (Parthasarathy et al., 1989; 
Sparrow et al., 1988). Other changes include an increase 
in the negative charge of the particle; the oxidation of 
cholesterol present in the LDL; the conversion of 
lecithin to lysolecithin via a phospholipase A2 (PLA2 ) 
activity intrinsic to LDL (Parthasarathy et al., 1985); 
the propagation of fatty acid fragmentation by the 
modified PUFA, and the attachment of these fragments to 
the apoprotein-Bl00 (apoB) present in LDL (Fong LG et 
al., 1987); and the possible fragmentation of apoB (Fong 
LG et al., 1987). The modified apoB was discovered to be 
the part of the molecule recognized by the macrophage 
scavenger receptor (Parthasarathy et al., 1987). Later 
studies showed that high concentrations of iron or copper 
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alone could mimic these results (Steinbrecher et al., 
1984). 
Having discovered an in vitro form of LDL that could 
induce foam cell formation, what was the evidence that 
this process occurred in vivo? Monoclonal antibodies 
(mAb) to oxLDL had been produced and detected material in 
lesions but not in lesion-free areas of arteries from 
Watanabe heritable hyperlipidemic (WHHL) rabbits. These 
mAb also recognized LDL isolated from these lesions. 
These investigators also discovered auto-antibodies to 
oxLDL in both rabbit and human sera (Palinski et al., 
1989). Yet the isolation of oxLDL from atherosclerotic 
lesions did not satisfactorily provide evidence for a 
causative role of oxLDL in lesion formation. This 
evidence came in part from an experiment in the 
laboratory of Carew (Carew et al., 1987), which used WHHL 
rabbits. These rabbits are genetically bred to be LDL-
receptor deficient, yet still develop lesions when fed 
high cholesterol diets. When treated with the powerful 
antioxidant probucol, the rate of fatty streak 
development decreased significantly. More importantly, 
the uptake and degradation of LDL by lesion macrophages 
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decreased by 50%. Probucol, which is transported in the 
LDL particle, had also been shown to prevent oxidative 
modifications of LDL and the resultant increase in 
macrophage degradation in vitro; and probucol 
significantly increased the ex vivo resistance to 
oxidation of LDL in humans (Parthasarathy, 1986b). 
Additional evidence for a role of LDL in athero-
genesis came in two areas. The first involved the role of 
monocyte recruitment and retainment. In addition to 
monocyte chemoattractants produced by EC (Quinn et al., 
1987), SMC (Mazzone et al., 1983; Valente et al., 1988), 
and macrophages (Mazzone et al., 1983), it was shown that 
oxLDL, directly and by itself, was chemotactic for human 
monocytes (Quinn et al., 1987). Additionally, oxLDL was 
shown to inhibit macrophage motility (Quinn et al., 
1985), implying a role in keeping macrophages and foam 
cells from leaving the lesion. The second area of 
involvement was that of cytotoxicity. oxLDL was shown to 
be highly cytotoxic to fibroblasts (Morel et al., 1983; 
Morel et al., 1984), SMC, and EC (Hessler et al., 1979; 
Morel et al., 1984). As mentioned earlier, Ross and 
Glomset had recognized the importance of endothelial 
13 
injury in atherogenesis. Although denudation does not 
occur before fatty streak formation (Davies et al., 
1976), EC loss does occur over fatty streaks (Faggiotto 
et al., 1984; Gerrity, 1981b). The cytotoxicity of oxLDL 
could lead to EC changes which would promote monocyte 
recruitment and endothelial denudation. 
All of this evidence for the involvement of LDL in 
atherogenesis led Daniel Steinberg et al. (1989) to 
propose a new hypothesis concerning the initiation of 
fatty streak formation. 
The Lipid Infiltration Hypothesis 
In 1989 several investigators who contributed many 
of the discoveries noted above came together to propose 
the lipid infiltration hypothesis as a means of 
explaining fatty streak formation. In it they hypothesize 
that increased plasma LDL levels lead to increased 
intimal LDL levels. Here, a basal rate of LDL oxidation 
by EC, SMC, and macrophages leads to the formation of 
oxLDL. This oxLDL is chemotactic for monocytes, which 
migrate subendothelially and differentiate into 
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macrophages, whose motility is inhibited by the oxLDL. 
The macrophages then further modify intimal LDL producing 
additional oxLDL and increasing the effects of oxLDL. 
Macrophages also uptake oxLDL via the scavenger receptor, 
resulting in foam cell formation. Meanwhile, 
extracellular oxLDL has two additional effects. It is 
cytotoxic, and can lead to EC injury; and it is 
immunogenic, leading to the formation of immune complexes 
which are taken up by macrophages via the F0 receptor 
(Brown and Goldstein, 1983). 
This hypothesis was not proposed to be mutually 
exclusive of the Response-to-Injury hypothesis. On the 
contrary, it's authors felt that the cytotoxicity of 
oxLDL could provide the EC injury which was important in 
the earlier hypothesis, thus integrating the two 
hypotheses. 
While it explained a key role of LDL in athero-
genesis, it did not explain why or how LDL accumulated in 
the arterial intima. The artery wall is known to be 
continuously permeated by lipoproteins (Lp), including 
LDL (Vasile et al. 1983), but most of these exit via the 
lymphatic system. However, in the presence of hyper-
15 
cholesterolemia LDL is taken up and degraded by the 
endothelium. This massive influx of modified LDL is 
concurrent with alterations in the ECM which lead to LDL 
trapping (Simionescu et al., 1986). It has been shown 
that when complexed with glycosaminoglycans or 
chondroitin sulfate-proteoglycan, components of the ECM, 
LDL uptake by macrophages is considerably increased 
(Camejo et al., 1991). This implies a role for ECM 
trapping, and suggests that this may be a local defense 
reaction, as monocyte migration and differentiation 
subsequently occur. It is assumed that the modifications 
to LDL by EC prime it for further oxidation in the intima 
(Witztum and Steinberg, 1991). 
So how do lipoproteins get transported across the 
endothelium? There may not be one specific answer. It is 
known that a small amount of LDL is endocytosed by EC. 
However, it was found that during hyperlipidemia, most Lp 
are transcytosed in a receptor-independent manner via 
plasmalemmal vesicles (Vasile et al., 1983). In an 
experiment using rabbits, ~-VLDL (very low density 
lipoprotein) was found to be transported in this manner 
early in hypercholesterolemia (Simionescu et al., 1986). 
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These vesicles then accumulated extracellularly in the 
intima, and have been dubbed extracellular liposomes 
(EL). At this stage, the endothelium was physically 
intact and there was no monocyte or platelet involvement. 
These EL have been observed in WHHL rabbits (Nievelstein 
et al., 1991) and humans (Chao et al., 1990). They have 
immunoreactive apoB fragments on their surface (Mora et 
al., 1987), and can be obtained from LDL in vitro by 
cholesteryl ester hydrolysis (Chao et al., 1992). 
However, in rats it was shown that LDL can cross the 
endothelium at intercellular junctions which are 
transiently opened during EC turnover (Lin et al., 1989). 
Hence there are at least three possible methods by which 
intimal LDL accumulation can occur. 
The transcytosed Lp undergo physicochemical 
modification and reassembly of their components (Guyton 
et al., 1991; Simionescu et al., 1986). These 
extracellular products have been called modified and 
reassembled lipoproteins (MRLp). In addition to EL, two 
other forms have been found in prelesional stages, that 
is before the involvement of monocytes. The first is self 
aggregates, which have an increased uptake by macrophages 
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(Khoo et al., 1988) but are more resistant to oxidation 
than nLDL (Hermann and Gmeiner, 1992). These have been 
demonstrated in rabbit arteries only two hours after a 
bolus infusion of Lp (Nievelstein et al., 1991). The 
second form is lipid droplets, which have also been 
formed in vitro by the aggregation of LDL (Guyton et al., 
1991). In aortas collected from rabbits during the 
prelesional stage (Mora et al., 1990), the crude MRLp 
fraction had a 3-fold increase in oxidative products, and 
also contained phospholipids, fragmented apoB, and 
increased amounts of unesterified cholesterol. When 
isolated separately, the EL fraction had only 
phospholipids, unesterified cholesterol, and surprisingly 
albumin at the EL core. This presence of albumin, a 
powerful antioxidant, further attests to a local defense 
reaction. Albumin has been shown to prevent LDL oxidation 
and the formation of MRLp in cell-free systems (Dobrian 
et al., 1993). 
Once MRLp have collected beneath the endothelium, 
they can induce constitutive changes in the overlying EC 
in conjunction with the continuing hypercholesterolemia 
(Simionescu and Simionescu, 1993). These changes can 
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include impairment of the EC response to specific 
stimuli; impairment of nitric oxide (NO) production, a 
vasodilatory mediator, which can lead to an increased 
risk of vasospasm; secretion of growth factors and 
cytokines such as PDGF and IL-1, which is believed to 
increase the adhesivity of EC for monocytes; production 
of MCP-1 (monocyte chemotactic protein 1) (Cushing et 
al., 1990), which is chemotactic specifically for 
monocytes and regulates EC adhesion molecules; secretion 
of PAI-1 (plasminogen activator inhibitor 1) which can 
lead to a decrease in the antithrombotic character of the 
endothelium (Libby and Hansson, 1991); and increased EC 
mitosis and possibly cell death, which can increase the 
permeability of the endothelium to Lp. In advancing 
lesions, EC may even become foam cells, leading to 
endothelial denudation. 
All of this evidence led Maya and Nicolae Simionescu 
to propose in 1993 an expanded theory for the development 
of atherosclerotic lesions. 
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Theory of Prelesional Changes in the artery wall 
In this unnamed theory, the researchers concentrated 
on events occurring in the artery wall before the 
involvement of monocytes. They proposed that increased 
concentrations of plasma LDL creates a concentration 
gradient across the endothelium, which leads to increased 
endothelial transport of LDL, primarily by transcytosis. 
These transported Lp are chemically modified, especially 
by lipid peroxidation. The exact location of these 
changes are still not known, and probably consist of more 
than one mechanism. These Lp then associate in one of the 
three forms mentioned earlier, that is self aggregates, 
lipid droplets, or EL, which are trapped by the ECM. The 
combination of MRLp on the abluminal side of the EC, and 
hypercholesterolemia on the luminal side induces 
constitutive changes in the EC without physical 
alteration. The EC then produce chemoattractants and 
monocyte adhesion molecules, following which monocytes 
"roll" across the endothelium, bind the adhesion 
molecules, and migrate through EC junctions to the 
subendothelium under the influence of oxLDL. These 
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monocytes then differentiate into macrophages, uptake and 
degrade large amounts of the MRLp, and transform into 
foam cells, now defining a fatty streak lesion. Growth 
factors produced by local cells then stimulate SMC 
migration and proliferation into the intima, leading to 
an advanced lesion. Eventually, calcification, necrosis, 
and thrombosis occur which leads to the advanced 
obstructive fibrous plaque. 
Simionescu and Simionescu (1993) concluded that it 
is not feasible to determine exactly the events leading 
to atherosclerosis in humans, and that a unified, 
coherent hypothesis of atherogenesis is yet to come. They 
felt that LDL oxidation begins as a protective mechanism 
aimed at allowing it's uptake by macrophages, and that 
the atherogenic process is a local defense reaction. 
Unfortunately, this reaction rapidly leads to EC 
dysfunction, and the eventual atherosclerotic plaque. A 
summary of the events in atherogenesis based on current 
knowledge and an integration of the above hypotheses is 
presented in Tables 1 and 2. 
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Table 1. Summary of Events in Early Atherosclerotic Lesion Formation. 
Fatty Streak Formation 
Stage Ia - Initiating Events 
• Increased plasma [LDLJ create a concentration gradient across the endothelium. 
• This leads to an increased intimal [LDL J via three mechanisms: 
- EC transcytose LDL in a R.,-independent manner yielding mmLDL/oxLDL. 
- EC endocytose LDL via a specific R.,. 
- LDL crosses at cell junctions during EC turnover. 
• A basal rate ofLDL oxidation by EC, SMC, and MO exists 
(possibly via free radicals). 
• Increased intimal [LDL] lead to ECM trapping ofLDL and ECM-LDL complex 
formation. 
• Monocytes are recruited via three mechanisms: 
- mmLDL induces EC production ofMCP-1 and IL-1. 
- oxLDL is directly chemotactic for monocytes. 
• Monocytes adhere to EC via pseudopodia then migrate to the subendothelium. 
• Monocytes differentiate into MO. 
• MO, via the scavenger R.,, have an increased uptake of: 
-oxLDL. 
- ECM-LDL complexes. 
- glycosylated LDL (as in Diabetes). 
• MO, via the F .,R, have an increased uptake of: 
- LDL immune complexes. 
• Lipid-laden MO become foam cells, leading to the characteristic fatty streak. 
Stage lb - Concurrent events during and after monocyte and LDL accumulation 
• MO, EC, and monocytes oxidize LDL. 
•oxLDL: 
- prevents MO migration (departure). 
- is cytotoxic to SMC and EC. 
- inhibits EC production of the vasodilators: 
- PGI2, which also inhibits platelet aggregation. 
-EDRF/NO. 
• MO produce IL-1, a monocyte chemotactic factor. 
Abbreviations used: EC - endothelial cells; R., - receptor; mmLDL - minimally modified LDL; 
oxLDL - oxidized LDL; SMC - smooth muscle cells; MO - macrophages; ECM - extracellular 
matrix; MCP-1-monocyte chemotactic protein-1; IL-1 - interleukin-1; F,R- receptor for 
immunoglobulin; PGI, - prostacyclin; EDRF/NO - endothelium derived relaxing factor/nitric 
oxide. 
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Table 2. Summary of Events in Advanced Atherosclerotic Lesion Formation. 
Stage II - Advanced Lesion Formation 
• EC injwy from oxLDL leads to: 
- increased EC turnover (also influenced by MO growth factors). 
- focal desquamation by means of: 
-EC death. 
- EC retraction 
- secretion of growth factors. 
• Exposure of the subendothelium leads to: 
- Platelet adherence to subendothelial collagen. 
- Platelet aggregation and release of: 
- PF 4, a monocyte chemoattractant. 
- TXA2, a promoter of aggregation. 
- PDGF, a monocyte and SMC chemoattractant plus a factor for SMC 
proliferation. 
• Platelet aggregation leads to: 
- mural thrombus formation. 
- possible vessel occlusion. 
• SMC proliferation leads to: 
- additional oxidation ofLDL 
- additional production of monocyte chemoattractants. 
- additional production ofECM components. 
- uptake of oxLDL by SMC leading to additional foam cells. 
• oxLDL cytotoxicity leads to foam cell necrosis, giving an extracellular lipid core. 
Stage III - Occlusive Thrombus Fonnation 
• EC take up oxLDL leading to: 
- additional foam cells. 
- additional denudation. 
• A fibrous cap of SMC and ECM occurs. 
• Plaque rupture can occur, leading to an occlusive thrombus. 
Abbreviations used: EC - endothelial cells; oxLDL - oxidized LDL; MO - macrophages; PF 4 -
platelet factor 4; TXA2 - thromboxane A2; PDGF - platelet derived growth factor; SMC -
smooth muscle cells; ECM - extracellular matrix. 
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Antioxidants 
Since most research points to the oxidation of LDL 
as a key event in the initiation of the atherosclerotic 
lesion, it is only natural to ask what can be done to 
prevent this from happening. Much research has been 
devoted to the effects of antioxidants and their possible 
role in the prevention of atherogenesis. While mention 
will be made of some of the synthetic antioxidants in 
use, the natural antioxidant vitamin E will be 
concentrated upon. The effects of antioxidants on 
platelet function will be discussed in a subsequent 
section. 
Vitamin E, or a-tocopherol, is the major lipid-
soluble, chain-breaking (i.e. peroxyl radical-trapping) 
antioxidant in human plasma. This is true in normal and 
severe vitamin E-deficient states (Ingold et al., 1987). 
It is also transported in the LDL particle, with an 
average of six a-tocopherol molecules per LDL particle 
(Esterbauer, 1992). It is thought to increase membrane 
stability by decreasing permeability and interacting with 
polyunsaturated phospholipids (PUPL) (Diplock et al., 
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1977; Maggio et al., 1977). 
The in vitro antioxidant effects of vitamin E have 
been found to be somewhat variable. Several studies have 
found it to prevent the oxidation of LDL by EC, SMC, 
monocytes, PMN (polymorphonuclear) cells, and iron 
(Cathcart et al., 1985; Lindsey et al., 1985; 
Steinbrecher et al., 1984). It was shown to prevent cu2+-
mediated oxidation at five but not 24 hours (Jialil et 
al., 1990); and similar results were obtained for the 
iron-mediated oxidation of PUPL when it was used in 
physiological concentrations (Leung et al., 1981). 
Finally, it was unable to prevent oxidation of LDL 
induced by ultraviolet radiation (Negre-Salvayre et al., 
1991). However, a-quinone, a highly oxidized product of 
vitamin E, has been shown to equally inhibit the 
oxidation of LDL by SMC and iron (Lindsey et al., 1985). 
This raises questions involving vitamin E as an 
antioxidant, so the role of vitamin E needs further 
investigation. 
In addition to research on the role of vitamin E as 
an antioxidant, work has also been conducted on a 
possible role in the prevention of biological 
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consequences such as cytotoxicity by previously oxidized 
LDL. Again, the results have been variable. One report 
found that it prevented the cytotoxicity of previously 
oxidized LDL (Negre-Salvayre et al., 1991), while another 
found that it did not prevent cytotoxicity, although it 
did prevent the formation of cytotoxic LDL (Morel et al., 
1983). This lends further support to the concept that LDL 
oxidation leads to cytotoxicity. 
While the results of in vitro experiments have 
differed, epidemiological studies conducted have been 
remarkably in agreement. There has been shown to be a 
significant inverse correlation between oral vitamin E 
intake and plasma concentrations of vitamin E, and the 
incidence of angina, coronary heart disease (CHD), and 
mortality from CHD (Gey et al., 1991; Riemersma et al., 
1991; Rimm et al., 1993; Stampfer et al., 1993). This was 
true for both males and females, even when adjusting for 
several other risk factors. 
Yet epidemiologic studies can not provide a cause-
and-effect relationship. There are too many unknown and 
uncontrolled variables. For this reason, several studies 
have been conducted on the effects of controlled vitamin 
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E supplementation in both animals and humans. 
In rabbits fed a high cholesterol diet, vitamin E 
completely inhibited the increase in LDL oxidation seen 
in rabbits not given vitamin E (controls). It also 
significantly inhibited the fall in prostacyclin (PGI 2 ) 
production seen in controls (Szczeklik et al., 1985). 
PGI 2 is an endothelium-derived vasodilator, and it's 
production is often decreased in atherosclerotic disease. 
PGI 2 also inhibits platelet aggregation and release 
(Aviram et al., 1985). 
In rats, various levels of vitamin E supplementation 
significantly reduced the amount of lipid peroxidation 
products present in plasma (Lenz et al., 1991; Umegaki et 
al., 1991), urine (Lee HS et al., 1992), and liver tissue 
(Lee and Csallany, 1987) when compared to controls. In 
the studies that measured oxidation of lipids in plasma, 
LDL oxidation was not determined. As in rabbits, vitamin 
E also attenuated the fall in PGI 2 production seen in 
control rats (Karpen et al., 1981). 
Several factors have been studied in humans 
supplemented with vitamin E. It should be noted that a 
wide range of dosages and lengths of supplementation have 
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been tested, and it is possible that these variances 
could cause conflicting results. These variables will be 
discussed in appropriate cases. 
None of the studies showed a change in the levels of 
plasma lipids (total cholesterol (TC), LDL, high density 
lipoprotein (HDL), and triglycerides (TG)) (Dieber-
Rothender et al., 1991; Jialil and Grundy, 1992; Salonen 
et al., 1991; Szczeklik et al., 1985). All of the studies 
found that the supplement was absorbed, as plasma, LDL, 
and platelets had significantly increased concentrations 
of vitamin E (Belcher et al., 1993; Dieber-Rothender et 
al., 1991; Jialil and Grundy, 1992; Kockmann et al., 
1988; Princen et al., 1992; Stampfer et al., 1988; 
Szczeklik et al., 1985). These studies found that 
supplementation significantly decreased the amount of 
oxLDL present in plasma (Lake et al., 1977; Salonen et 
al., 1991; Szczeklik et al., 1985). When subjected to ex 
vivo oxidation using cu2•, heme, or cell-mediated systems, 
the rate of oxidation was found to be significantly 
decreased (Jialil and Grundy, 1992; Princen et al., 
1992); while the resistance to oxidation was 
significantly increased, by as much as 75% (Belcher et 
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al., 1993; Dieber-Rothender et al., 1991; Jessup et al., 
1990; Mackness et al., 1993; Princen et al., 1992; Reaven 
et al., 1993). Only one study found no correlation 
between oxidative resistance and the concentration of 
vitamin E in LDL (Jessup et al., 1990). One study looked 
at the ex vivo cytotoxicity to EC by the supplemented 
LDL, and found it to be significantly decreased (Belcher 
et al., 1993). Finally, two studies found that, unlike in 
animals, PGI2 production was not altered (Fitzgerald and 
Brash, 1982; Stampfer et al., 1988). However, both 
studies were measuring plasma levels of PGI 2 , a paracrine 
signal molecule. 
Probucol is the most significant synthetic anti-
oxidant for which studies have been conducted. It has 
been shown to totally inhibit the in vitro oxidation of 
LDL by several methods (Balla et al., 1991; McLean and 
Hagaman, 1989; Parthasarathy, 1986b); to significantly 
decrease intimal lipid accumulation and macrophage uptake 
of LDL in rats (Shankar et al., 1989); and to 
significantly increase the resistance of plasma LDL to 
oxidation in rabbits (Kita et al., 1987) and humans 
(Parthasarathy, 1986b). 
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Antioxidants. Low Density Lipoprotein and Platelets 
As discussed earlier, platelets have been shown to 
play an important role in the formation of advanced 
atherosclerotic lesions. They circulate in the blood in 
an inactive state, unable to bind to normal endothelium. 
However, platelets readily bind to injured endothelium, 
as platelet stimulants such as collagen are exposed. 
Platelets initially bind in a single layer, a process 
known as adhesion. The platelets then release contents 
stored in their granules which promote vasoconstriction 
and assist in the process of aggregation, or the 
formation of a platelet plug. One of the molecules 
released is S-thromboglobulin (S-TG), which binds 
specific receptors on EC and inhibits PGI 2 production 
(Hope et al., 1979). It can be used to quantitate in vivo 
platelet activation (Williams et al., 1985). Aggregation 
is mediated by the binding of fibrinogen between 
GPIIB/IIIA complexes on adjacent platelets, which are 
exposed upon activation (Coller, 1986). Concurrently, the 
blood coagulation cascade may be occurring. This leads to 
the formation of a fibrin web around the platelet plug, 
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giving a fibrin clot. While this process is intended to 
control bleeding in a severed vessel, it's initiation by 
endothelium injured by atherosclerotic processes leads to 
the formation of a mural thrombus. This may eventually 
lead to occlusion of the artery, with resulting ischemia 
and possible tissue infarction distal to the site of the 
occlusion. 
Several platelet interactions occur in athero-
sclerosis which promote the formation of advanced 
lesions. As discussed earlier, PDGF, which is released 
during platelet activation, is a SMC mitogen and is 
chemotactic for both SMC and monocytes. Thus, it's 
release can increase monocyte involvement and induce SMC 
proliferation into the intima. As SMC can form ECM (Burke 
and Ross, 1979), this complicates the lesion and can 
increase the uptake by macrophages of LDL which become 
complexed with ECM components. PDGF has also been shown 
to increase the number of LDL receptors on SMC, leading 
to increased uptake and degradation of LDL (Chait et al., 
1980). This can lead to additional foam cell formation. 
Platelets also interact with cholesterol, leading to 
inappropriate responses. Platelets have a specific 
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receptor for LDL (Aviram et al., 1981) which has been 
shown to recognize nLDL and oxLDL with the same affinity 
(Pedreno et al., 1994). This receptor has been shown to 
be different from the LDL receptor on nucleated cells 
(Pedreno et al., 1992), and may be a part of the 
GPIIb/IIIa complex (Koller et al., 1989), although this 
interpretation has been questioned (van Willigen et al., 
1994). LDL significantly increases platelet release of 
~-TG (Aviram and Brook, 1984). This is one of the ways in 
which LDL enhances aggregation. Nearly all studies have 
shown that regardless of its state of oxidation, LDL 
significantly increases in vitro aggregation in response 
to ADP (Ardlie et al., 1989; Hassall et al., 1983; Naseem 
et al., 1993; van Willigen et al., 1994), thrombin 
(Ardlie et al., 1989; Aviram and Brook, 1983; Aviram et 
al., 1985; Naseem et al., 1993; Shmulewitz et al., 1984), 
and epinephrine (Ardlie et al., 1989; Hassall et al., 
1983). Oxidized LDL has even been shown to produce 
aggregation in the absence of other agonists (Ardlie et 
al., 1989; Naseem et al., 1993). Only one study showed a 
decrease in platelet aggregation in the presence of LDL, 
and this was only when using nLDL (Naseem et al., 1993). 
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These proaggregatory effects were abolished when the LDL 
binding protein was modified (Hassall et al., 1983; 
Shmulewitz et al., 1984; van Willigen et al., 1994), 
implying that LDL must bind to platelets before inducing 
an effect. LDL may enhance aggregation by promoting an 
increase in the binding of fibrinogen to platelets 
(Naseem et al., 1993; van Willigen et al., 1994). 
Similarly, ex vivo studies have shown that platelets from 
both hypercholesterolemic humans (Carvalho et al., 1974; 
Shattil et al., 1977) and rats (Winocour et al., 1989) 
have significantly increased aggregation in response to 
several stimuli. One study (Shattil et al., 1977) showed 
that the cholesterol concentration of platelet membranes 
was increased. Another study showed that LDL decreased 
platelet membrane fluidity (Ardlie et al., 1989). These 
findings seem to point to a possible role of changes in 
membrane stability in aggregation. 
Clearly, hypercholesterolemia and platelet aggre-
gation and release are intertwined with atherogenesis. 
Therefore, much research has been performed to determine 
whether antioxidants can reduce platelet interactions 
with atherosclerotic lesions. 
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In several in vitro studies, vitamin E inhibited or 
prevented platelet aggregation and release in response to 
arachidonic acid (AA), ADP, epinephrine, thrombin, and 
collagen (Agradi et al., 1981; Fong JSC, 1976; Kockmann 
et al., 1988; Srivastava, 1986; Steiner and Anastasi, 
1976; Steiner and Mower, 1982; White et al., i977). This 
occurred in a dose-dependent manner with the release 
reaction and AA-induced aggregation being especially 
susceptible. However, a-quinone was shown to equally 
inhibit aggregation (Mower and Steiner, 1982), suggesting 
that vitamin E may act through a mechanism other than 
it's antioxidant abilities. 
In vivo studies with vitamin E have provided very 
inconsistent results. In rats, platelet aggregation in 
response to collagen and ADP decreased significantly in 
the presence of vitamin E (Umegaki et al., 1991). In 
humans, platelet aggregation studies have given mixed 
results in regard to vitamin E. While most studies showed 
a decrease in AA-induced aggregation (Fitzgerald and 
Brash, 1982; Kockmann et al., 1988; Szczeklik et al., 
1985), studies were evenly split between a decrease and 
no change in aggregation when using ADP (Fitzgerald and 
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Brash, 1982; Lake et al., 1977; Salonen et al., 1991; 
Stampfer et al., 1988; Steiner, 1983; Szczeklik et al., 
1985) and epinephrine (Lake et al., 1977; Steiner, 1983). 
Dosages of vitamin E were comparable between the groups 
with decreased aggregation and the groups showing no 
change. The results for platelet adhesion, however, have 
been more promising. Supplementation has demonstrated a 
significant decrease in ex vivo platelet adhesion (Jandak 
et al., 1988; Jandak et al., 1989; Steiner, 1983). The 
decrease was inversely correlated with platelet membrane 
vitamin E concentrations, and was accompanied by a 
significant decrease in the number of extruded pseudo-
podia visible with scanning electron microscopy (Jandak 
et al., 1989). This further supports a role for vitamin E 
in membrane stabilization. Indeed, a separate study found 
that platelet membrane fluidity decreased significantly 
with supplementation (Steiner, 1991). Finally, plasma 
levels of ~-TG were found to be significantly reduced 
with supplementation, implying a decrease in in vivo 
platelet activation (Salonen et al., 1991). 
In our present study, we examined the effects of a 
high cholesterol diet and vitamin E supplementation in 
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rats on ex vivo platelet aggregation and the amounts of 
lipid peroxidation products present in plasma. We 
addressed two questions: (1) Does vitamin E 
supplementation alter ex vivo platelet aggregation 
induced by arachidonic acid and adenosine diphosphate in 
hypercholesterolemic rats?; and (2) Does vitamin E 
supplementation alter plasma levels of oxLDL as measured 
by thiobarbituric acid-reactive substances in 
hypercholesterolemic rats? 
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MATERIALS .AND METHODS 
Materials 
Thiobarbituric acid (TBA), Trichloroacetic acid 
(TCA), Tetramethoxypropane (TMP), Ethylenediamine-
tetraacetate (EDTA), Potassium Bromide (KBr), and bovine 
serum albumin (BSA) were obtained from Sigma Chemical 
Company. Bio-tal anesthetic (Thiamylal Sodium) was from 
Bio-Ceutic. Sterile normal saline was from Travenol. 
Adenosine Diphosphate (ADP) and Arachidonic acid (AA) 
reagents were obtained from Chrono-Log. 
Chemicals for the determination of total choles-
terol, HDL cholesterol, and triglycerides were obtained 
from Sigma Diagnostics. All other chemicals used were 
from Fisher Scientific. 
Male rats (275 g to 299 g) were obtained from Harlan 
Sprague Dawley. The animals were housed in the Lappin 
Hall animal facility, with alternating 12 hour periods of 
light and dark. Purina 5001 laboratory rodent diet with 
0.02% cholesterol and 49 mg of vitamin E per kg of diet 
was used as the normal (N) diet. A preparation of the 
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Purina 5001 diet with 5% cholesterol plus 1% sodium 
taurocholate represented the cholesterol (C) diet. The 
cholesterol preparation plus 300 mg of a-tocopherol 
acetate per kg of diet comprised the cholesterol plus 
vitamin E (E) diet. These two dietary preparations were 
obtained from Bio-Serv. The use of 300 mg of a-tocopherol 
was based on the prior work of Giani et al. (1985), in 
which supplementation of vitamin E to a diet containing 
heated fat potentiated the antiaggregatory activity of 
the arterial wall of rats, resulting in inhibition of 
platelet aggregation. 
Methods 
The male Sprague-Dawley rats were divided into three 
dietary groups, N, C, and E, containing 10, 10, and 11 
rats respectively. All rats were fed a diet of normal 
chow for two weeks. The C group was then switched to the 
cholesterol chow, while the E group was switched to the 
cholesterol chow supplemented with vitamin E. The N group 
continued to receive the normal chow. All groups were 
maintained on the appropriate diet for a minimum of eight 
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weeks. Food and water were supplied ad libitum. 
Specimen Collection 
Each rat was anesthetized by intraperitoneal 
injections of 15 mg Bio-tal per 100 g body mass. All 
blood was drawn using 3cc syringes with 22g one inch 
needles. Blood for the platelet aggregation studies was 
collected using 1 part of 3.4% trisodium citrate per 9 
parts of blood. Blood for all remaining studies was 
collected using 1 part of 10.0% EDTA (pH 7.4) per 9 parts 
of blood. 
The tail artery was used to collect as much blood as 
possible, with 6.0 ml representing the maximum amount 
obtained. The rat's abdominal cavity was then dissected, 
and blood was collected from the inferior vena cava. 
Appropriate samples were then transferred into a 12 ml 
polycarbonate centrifuge tube. After all samples were 




From the citrated blood, two aliquots of 0.5 ml each 
were dispensed into cuvettes containing 0.5 ml of Tyrodes 
solution and a stir bar. These samples were maintained at 
37 °C for use in the platelet aggregation studies. From 
the remaining sample, a hematocrit was determined using a 
micro-hematocrit tube. 
The EDTA blood was centrifuged in a Clay-Adams 
analytical centrifuge for 5 minutes to obtain plasma. The 
plasma was withdrawn and placed in a polypropylene tube, 
from which 600 - 800 µl was removed and placed in a 
separate tube for use in plasma lipid determinations. The 
remaining plasma sample in the polypropylene tube was 
used for LDL extraction. All the EDTA samples were stored 
at 4 °c. 
Platelet Aggregation studies 
Aggregation, induced by ADP and AA, was measured 
using a Chrono-Log whole blood aggregometer in accordance 
with procedures published by Chrono-Log Corporation 
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(Galvez et al., 1986). The agonists ADP and AA were 
prepared and kept wrapped in foil and on ice. To one of 
the samples (0.5 ml citrated blood plus 0.5 ml Tyrode's 
solution), 5 µl of 1 rnM ADP was added for a final 
concentration of 5 µM, while to the second sample 10 µl 
of 50 rnM AA was added for a final concentration of 0.5 
rnM. Aggregation was measured for a period of 5 minutes. 
Plasma Lipids Determination 
Total cholesterol (TC) was determined using a 
modification of the method of Allain et al. (1974) Sigma 
Diagnostics procedure No. 352. HDL cholesterol (HDL) was 
determined using a modification of the method of Warnick 
et al. (1982) Sigma Diagnostics procedure No. 352-3. 
Triglycerides (TG) were determined using a modification 
of the method of McGowan et al. (1983) Sigma Diagnostics 
procedure No. 339. Cholesterol calibrators and controls 
from Sigma Diagnostics were also used. Spectrophotometric 
readings were made with a Milton Roy model 1201 spectro-
photometer using polystyrene cuvettes (Sarstedt). 
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Isolation of LDL 
LDL was isolated using density gradient ultra-
centrifugation (Puhl et al., 1994). The KBr solutions 
were purged with N2 gas for 5 minutes before use. Beckman 
polyallomer tubes (13.2 ml) were used for the samples. 
Plasma was adjusted to a density of 1.22 using KBr. The 
density layers were added to the tube from the bottom up, 
starting with a solution of density (d) 1.005 (3.0ml). 
Beneath this was added the 1.05d KBr (3.0ml), then the 
1.08d KBr (3.0ml), and finally the 1.22d plasma sample 
(2.0ml). The tube was then filled with the 1.005d 
solution. The samples were then centrifuged in a Beckman 
XL-90 ultracentrifuge using an SW28 rotor with SW28.l 
buckets. The centrifugation was for 36 hours and 51 
minutes at 28000 rpm and 10 °C. This gave excellent 
separation of the various lipoproteins, with the LDL 
being the yellow, second layer from the top of the tube. 
The LDL was extracted using a syringe and needle, 
filtered through a 0.2 µM filter, purged with N2 , and 
stored in sterile 1.5ml polypropylene tubes at 4 °C. 
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Determination of Plasma Lipid Peroxides 
TEARS (thiobarbituric acid-reactive substances) were 
determined using a modification of the methods of Yagi 
(1976) and of Steinbrecher et al. (1984). The reaction 
mixture contained 1.5 ml of 0.67% thiobarbituric acid, 
1.5 ml of 20.0% trichloroacetic acid, and an aliquot of 
LDL representing 25 µg of LDL. This aliquot was 
determined by calculating the protein concentration from 
the LDL total cholesterol content (Puhl et al., 1994). 
The mixture was vortexed, and the solution heated for 30 
minutes in a 100 °C water bath. The samples which 
contained TEARS produced a pink color. The samples were 
cooled 5 minutes before adding 3.0 ml of n-butanol and 
vortexing. They were then allowed to stand until 
complete separation occurred. This resulted in the 
samples turning a golden yellow. The top layer was placed 
in cuvettes and fluorescence measured using a Perkin-
Elmer model 650-l0S fluorescence spectrophotometer with 
an excitation wavelength of 534 nm and an emission 
wavelength of 551 nm. Standards of 0.05 nM, 0.1 nM, 0.2 
nM, and 0.4 nM tetramethoxypropane, which yield 
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malondialdehyde (MDA), were used. Results are expressed 
as nanomoles of MDA equivalents. 
Data Analysis 
All statistics were performed using SAS and the GLM 
procedure (an ANOVA procedure for unbalanced numbers of 
samples). Differences between groups were determined 




Total cholesterol and LDL cholesterol were 
significantly increased in both diets supplemented with 
5% cholesterol (p<0.0001), but the cholesterol without 
vitamin E (C) and the cholesterol with vitamin E (E) 
groups were not different from each other (Table 3, 
Figures 1 and 4). Triglycerides were significantly higher 
in the E group only in comparison with the group not 
supplemented with cholesterol (N) (p<0.05, Table 2 and 
Figure 2). There was no diet-induced difference in HDL 
cholesterol levels (Table 2 and Figure 3). 
Platelet Aggregation 
There were no significant differences between the C 
and E group platelet aggregation responses to either 0.5 




Analysis of the LDL fractions revealed the presence 
of TBARS in both groups of rats which received dietary 
cholesterol. There was 38% less TBARS in the LDL fraction 
from the hypercholesterolemic rats which received the 
dietary supplement of vitamin E. This was statistically 
significant (p<0.02, Figure 7). 
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TABLE 3. 
Assayed values of plasma lipids in the normal diet group (N), 
cholesterol supplemented group (C), and cholesterol+ vitamin E 
supplemented group (E). 
Group 
N C 
Total Cholesterol1 50 ± 8.0 191 ± 44. 2• 
LDL1 6 ± 2.9 135 ± 34. 0• 
Triglycer ides1 33 ± 10.6 54 ± 26.8 
HDL1 38 ± 6.8 51 ± 21.2 
1 
- mg/dL (expressed as mean± standard deviation) 
' - p<0.0001 vs. N 











Measurements of platelet aggregation induced by 5 µM ADP (adenosine 
diphosphate) and 0.5 mM AA (arachidonic acid) in the normal diet 
group (N), cholesterol supplemented group (C), and cholesterol+ 
vitamin E supplemented group (E). 
Group 
N C 
AA aggregation' 7.02 ± 3.8 8.61 ± 4.4 
ADP aggregation1 7.47 ± 3.5 11.9 ± 7.1 
1 
- impedance change (ohms) 5 minutes after agonist 
addition (expressed as mean± standard deviation) 
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E 
6.22 ± 6.1 
8.54 ± 4.3 
N C E 
Figure 1. Plasma total cholesterol (TC) levels in the normal 
diet group (N), cholesterol supplemented group (C), and 
cholesterol+ vitamin E supplemented group (E). Both c and E 









N C E 
Figure 2. Plasma triglyceride (TG) levels in the normal diet 
group (N), cholesterol supplemented group (Cl, and 
cholesterol+ vitamin E supplemented group (El. Eis 
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Figure 3. Plasma HDL cholesterol levels in the normal diet 
group (N), cholesterol supplemented group (C), and 
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Figure 4. Plasma LDL cholesterol levels in the normal diet 
group (N), cholesterol supplemented group (C), and 
cholesterol+ vitamin E supplemented group (E). Both c and E 
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Figure 5. Comparison of arachidonic acid-induced platelet 
aggregation for the normal diet group (N), cholesterol 
supplemented group (C), and cholesterol+ vitamin E 
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Figure 6. Comparison of ADP-induced platelet aggregation for 
the normal diet group (N), cholesterol supplemented group 
(C), and cholesterol+ vitamin E supplemented group (E). 
There are no significant differences. 
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C E 
Figure 7. oxidized LDL as measured by TEARS (thiobarbituric 
acid-reactive substances) for the cholesterol supplemented 
group (C) and the cholesterol+ vitamin E supplemented group 
(E). Results for E are significantly lower than those for C 
(p<0.02) (MDA: malondialdehyde equivalents). 
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DISCUSSION 
As expected, cholesterol supplementation 
significantly increased plasma total cholesterol and low 
density lipoprotein (LDL) levels, regardless of vitamin E 
supplementation. Epidemiological studies have linked 
increases of these plasma lipids with accelerated 
atherogenesis and increased mortality from coronary heart 
disease (Keys, 1970). Evidence also strongly supports an 
important role for oxidatively modified LDL (oxLDL) in 
the pathogenesis of the early atherosclerotic lesion 
(Steinberg et al., 1989). It was for these reasons that 
the effects of an antioxidant on plasma levels of oxLDL 
as measured by thiobarbituric acid-reactive substances 
was investigated. We chose vitamin E because it is the 
major lipid-soluble, chain-breaking antioxidant in human 
plasma (Ingold et al., 1987); it is carried in the LDL 
particle (Esterbauer et al., 1992); it occurs naturally 
in many foods; and, unlike synthetic antioxidants such as 
probucol and butylated hydroxytoluene, it has no 
contraindications or serious side effects in humans in 
doses up to 1000 IU/day (Benich and Machlin, 1988). 
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Our studies showed that the cholesterol diet rats 
had oxidized LDL in plasma, as measured by TEARS; and 
that vitamin E supplementation (300 mg a-tocopherol 
acetate/kg diet) to the cholesterol diet significantly 
reduced TEARS in the LDL samples by 38%. Umegaki et al. 
(1991) reported that serum lipid peroxidation was reduced 
in rats administered vitamin E (26 mg/rat per os) every 
other day. However, that study did not isolate and 
analyze LDL for oxidation. LDL oxidation has not been 
found to occur in the presence of serum, and it has been 
suggested that LDL is not oxidized in the circulation in 
humans (Holvoet and Collen, 1994), although auto-
antibodies to oxLDL have been isolated from rabbit and 
human sera (Palinski et al., 1989). 
The level of antioxidant protection provided in this 
study could possibly prevent the formation of minimally 
modified LDL (mmLDL), a mildly oxidized form of LDL which 
is formed by the interaction of LDL with endothelial 
cells (EC), especially during transcytosis. It is mmLDL 
which initiates the formation of monocyte chemotactic 
protein-1 (MCP-1) by EC (Cushing et al., 1990). MCP-1 is 
the substance primarily responsible for the recruitment 
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of monocytes during the early stages of atherogenesis 
(Navab et al., 1991), a key step in the formation of the 
early atherosclerotic lesion. 
Abnormal platelet aggregation has been shown to play 
a key role in the formation of the advanced athero-
sclerotic lesion (Ross, 1986). The release of substances 
such as platelet-derived growth factor from activated 
platelets plays a large role in the migration and 
proliferation of smooth muscle cells from the media into 
the intima (Deuel et al., 1982; Ross et al., 1974). The 
resulting increase in plaque size and complexity, along 
with the possible rupture of the plaque, can lead to an 
infarction of tissues distal to the site of the plaque. 
Thus, it would be advantageous to find a safe method 
which would decrease platelet aggregation. 
In rats, vitamin E has been shown to significantly 
decrease platelet aggregation in response to both 
collagen and adenosine diphosphate (ADP). However, 
studies in humans have given mixed results, especially 
for ADP. For these reasons, the effects of vitamin E 
supplementation on platelet aggregation in response to 
ADP and arachidonic acid (AA) were studied. 
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Our studies showed that vitamin E supplementation 
decreased platelet aggregation in response to both 
agonists in hypercholesterolemic rats, but this decrease 
did not reach statistical significance. While this is not 
inconsistent with findings in humans for ADP, the great 
majority of studies showed a significant decrease in AA.-
induced platelet aggregation with vitamin E 
supplementation. Our results may have been influenced by 
the numbers of samples (n ranged from 5 to 8 for the 
cholesterol-supplemented groups); or by plasma and/or 
platelet vitamin E concentrations, a variable which was 
not measured in the current study. 
In conclusion, this study found that vitamin E 
supplementation significantly reduced the oxidation of 
LDL which occurred in hypercholesterolemic plasma, but 
did not significantly reduce the platelet aggregation 
responses to AA and ADP of hypercholesterolemic rats. 
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